Tianjin Kind Pharma Co., Ltd.
Assessed Supplier Enterprise Certification
- Assessed
Supplier - 1st
years
Assessed Supplier Enterprise Certification
Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Lab/Research institutions
Tel: +86-15510908448
Mobile: +86-15510908448
Tel: +86-15510908448
Fax: +86-15510908448
URL: http://www.kindpharma.biz
Province/state: Tianjin
City: Tianjin
Street: No.22 Quanwang Road, Wuqing Development Zone, Tianjin, China
MaxCard:
Contact Suppliers
CAS NO.1374743-00-6
Factory supply high purity 1374743-00-6 Trilaciclib with low price, accept customization.
Trilaciclib is an intravenous cell-cycle inhibitor developed by G1 Therapeutics. It functions as a short-acting inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Its primary purpose is to transiently maintain immune cells and hematopoietic stem and progenitor cells in G1 arrest. By doing so, trilaciclib aims to protect the immune system and bone marrow from chemotherapy-induced damage, potentially optimizing the antitumor activity while minimizing myelotoxicity.
Mechanism of Action:
Target: Cyclin-dependent kinases (CDK) 4 and 6.
Action:
Induces reversible cell cycle arrest in the G1 phase.
Temporarily arrests hematopoietic stem and progenitor cells.
Protects bone marrow and the immune system from chemotherapy-induced damage.
Indication:
Used to reduce the frequency of chemotherapy-induced bone marrow suppression.
Specifically indicated for adult patients receiving platinum/etoposide-containing regimens or topotecan-containing regimens for extensive-stage small cell lung cancer (ES-SCLC).
Approval:
Trilaciclib (Cosela) received its first approval in the USA in February 2021 for the mentioned indication.
Administration:
Administered by intravenous infusion prior to chemotherapy.
Given on each day the chemotherapy is administered.
Clinical Use:
Administered to decrease the incidence of chemotherapy-induced myelosuppression.
It is crucial for healthcare providers to follow recommended administration protocols and monitor patients for any adverse effects during the treatment course. Trilaciclib's mechanism of action, providing temporary protection to hematopoietic cells, contributes to its potential as a myeloprotective agent in the context of chemotherapy.